Top Analyst Reports for Microsoft, Amazon.com & Philip Morris
Microsoft, Amazon.com and Philip Morris headline fresh analyst reports highlighting AI, cloud, and smoke-free growth momentum.
Zacks·3d ago
More News
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
Zacks·5d ago
Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind
The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.
Stocktwits·13d ago
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.
Stocktwits·26d ago
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic
Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.
Stocktwits·26d ago
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease
Brinsupri, an oral, once-daily treatment, is now the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis, the company said.
Stocktwits·27d ago
Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock
Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Zacks·28d ago
Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Insmed (INSM) delivered earnings and revenue surprises of -30.77% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +216.67% and +12.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?